{"doi":"10.1111/jocs.16942","title":"Impact of preoperative Impella support on destination left ventricular assist device outcomes","abstract":null,"journal":"Journal of Cardiac Surgery","year":2022,"id":662351,"datarank":0.38474240361923057,"base_score":2.5649493574615367,"endowment":2.5649493574615367,"self_citation_contribution":0.38474240361923057,"citation_network_contribution":0.0,"self_endowment_contribution":0.38474240361923057,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":12,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1729085,"name":"Justin M. Schaffer","orcid":null,"position":1,"is_corresponding":false},{"id":1729086,"name":"Katherine B. Harrington","orcid":null,"position":2,"is_corresponding":false},{"id":1729088,"name":"Talia G. Meidan","orcid":null,"position":3,"is_corresponding":false},{"id":1729090,"name":"John Michael DiMaio","orcid":null,"position":4,"is_corresponding":false},{"id":1729092,"name":"Nitin Kabra","orcid":null,"position":5,"is_corresponding":false},{"id":1729094,"name":"David A. Rawitscher","orcid":null,"position":6,"is_corresponding":false},{"id":1321765,"name":"Aasim Afzal","orcid":"0000-0003-1557-8190","position":7,"is_corresponding":false},{"id":1321766,"name":"Timothy J. George","orcid":"0000-0003-0953-0895","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Impact of preoperative Impella support on destination left ventricular assist device outcomes","abstract":"BACKGROUND: Although left ventricular assist device (LVAD) implantation is associated with improved heart failure survival, the impact of pre-implantation Impella support on outcomes is unknown. We undertook this study to evaluate the impact of preoperative Impella support on LVAD outcomes. METHODS: We conducted a retrospective review of all Heartmate 3 LVAD implants. Primary stratification was by the need for preoperative Impella support with the 5.0/5.5 device. Longitudinal survival was assessed by the Kaplan-Meier method. Multivariable Cox proportional hazards regression models were developed to evaluate mortality. Secondary outcomes included changes in laboratory values during Impella support. RESULTS: From 2017 to 2021, 87 patients underwent LVAD implantation. Sixteen were supported with a single inotrope, 36 with dual inotropes, 27 with Impella, and 3 with extracorporeal membrane oxygenation (ECMO). When stratified by the need for Impella, there was no difference in survival at 30-days (98.3 [88.2-99.8]% vs. 96.3 [76.5-99.5]%, p = .59), 1-year (91.0 [79.8-96.2] vs. 74.9 [51.7-88.2], p = .10), or at 2 years (87.9 [74.3-94.5] vs. 74.9 [51.7-88.2], p = .15). On multivariable modeling, the need for preoperative Impella was not associated with an increased hazard of 1-year (1.24 [0.23-6.73], p = .81) or 2-year mortality (1.05 [0.21-5.19], p = .95). After 7 (5-10) days of Impella support, recipient creatinine (p < .01), creatinine clearance (p = .02), and total bilirubin (p = .053) improved and lactic acidosis resolved (p < .01). CONCLUSIONS: Preoperative Impella support is not associated with increased short or long-term mortality but is associated with improved renal and hepatic function as well as total body perfusion before LVAD implantation.","is_dataset_classified":null,"base_score":2.5649493574615367,"endowment":2.5649493574615367,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36124428","pmcid":null,"openalex_id":"https://openalex.org/W4296482087","authors":[],"funders":[],"total_grants":0,"fwci":0.7154,"citation_percentile":0.63236408,"influential_citations":0,"citation_trend":[{"year":2022,"count":1},{"year":2023,"count":1},{"year":2024,"count":4},{"year":2025,"count":4},{"year":2026,"count":2}],"oa_status":"closed","license":"http://doi.wiley.com/10.1002/tdm_license_1.1","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jocs.16942","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/full-xml/10.1111/jocs.16942","host_type":"publisher"},{"url":"https://doi.org/10.1111/jocs.16942","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/36124428","host_type":"repository"}],"fields_of_study":["Mechanical Circulatory Support Devices","Prosthetics and Rehabilitation Robotics","Cardiac Structural Anomalies and Repair"],"mesh_terms":["Bilirubin","Creatinine","Heart Failure","Heart-Assist Devices","Humans","Retrospective Studies","Extracorporeal Membrane Oxygenation","Treatment Outcome"],"keywords":["Impella","Medicine","Ventricular assist device","Creatinine","Extracorporeal membrane oxygenation","Proportional hazards model","Hazard ratio","Internal medicine","Retrospective cohort study","Cardiology","Inotrope","Heart failure","Surgery","Confidence interval","Transplant","Perfusion","Cardiovascular Pathology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-12T14:03:27.978486Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}